Literature DB >> 22248680

Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database.

Andrew W ElBardissi1, Sary F Aranki, Shubin Sheng, Sean M O'Brien, Caprice C Greenberg, James S Gammie.   

Abstract

OBJECTIVE: Coronary artery bypass grafting (CABG) is the operation most commonly performed by cardiac surgeons. There are few contemporary data examining evolving patient characteristics and surgical outcomes of isolated CABG. We used the Society of Thoracic Surgeons adult cardiac surgery database to characterize trends in patient characteristics and outcomes after CABG over the past decade.
METHODS: From 2000 to 2009, 1,497,254 patients underwent isolated primary CABG at Society of Thoracic Surgeons participating institutions. Demographics, operative characteristics, and postoperative outcomes were assessed, and risk-adjusted outcomes were calculated.
RESULTS: Compared with the year 2000, patients undergoing isolated primary CABG in 2009 were more likely to have diabetes mellitus (33% vs 40%) and hypertension (71% vs 85%). There were clinically insignificant differences in age, gender, and body surface area. Between 2000 and 2009, there has been a 6.3% and 19.5% increase in the preoperative use of aspirin and beta-blockers, respectively. Between 2004 and 2009, there was a 7.8% increase in the use of angiotension-converting enzyme inhibitors preoperatively. Furthermore, between 2005 and 2009 there was a 3.8% increase in the use of statins preoperatively. The median number of distal anastomoses performed was unchanged between 2000 and 2009 (3; interquartile range, 2-4). There was a significant increase in the use of the internal thoracic artery (88% in 2000 vs 95% in 2009). The predicted mortality rates of 2.3% were consistent between 2000 and 2009. The observed mortality rate over this period declined from 2.4% in 2000 to 1.9% in 2009 representing a relative risk reduction of 24.4%. The incidence of postoperative stroke decreased significantly from 1.6% to 1.2%, representing a risk reduction of 26.4%. There was also a 9.2% relative reduction in the risk of reoperation for bleeding and a 32.9% relative risk reduction in the incidence of sternal wound infection.
CONCLUSIONS: Over the past decade, the risk profile of patients undergoing CABG has changed, with fewer smokers, more diabetic patients, and better medical therapy characterizing patients referred for surgical coronary revascularization. The left internal thoracic artery is nearly universally used and outcomes have improved substantially, with a significant decline in postoperative mortality and morbidity.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248680     DOI: 10.1016/j.jtcvs.2011.10.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  82 in total

1.  In Reply.

Authors:  Miklos D Kertai; Shan Zhou; Jörn A Karhausen; Mary Cooter; Edmund Jooste; Yi-Ju Li; William D White; Solomon Aronson; Mihai V Podgoreanu; Jeffrey Gaca; Ian J Welsby; Jerrold H Levy; Mark Stafford-Smith; Joseph P Mathew; Manuel L Fontes
Journal:  Anesthesiology       Date:  2016-08       Impact factor: 7.892

2.  The challenge of achieving 1% operative mortality for coronary artery bypass grafting: a multi-institution Society of Thoracic Surgeons Database analysis.

Authors:  Damien J LaPar; Giovanni Filardo; Ivan K Crosby; Alan M Speir; Jeffrey B Rich; Irving L Kron; Gorav Ailawadi
Journal:  J Thorac Cardiovasc Surg       Date:  2014-07-24       Impact factor: 5.209

3.  The second best arterial graft to the left coronary system in off-pump bypass surgery: a propensity analysis of the radial artery with a proximal anastomosis to the ascending aorta versus the right internal thoracic artery.

Authors:  Hiroshi Tsuneyoshi; Tatsuhiko Komiya; Takeshi Shimamoto; Jiro Sakai; Toshifumi Hiraoka; Takashi Kawashima; Genya Muraoka; Masato Fujimoto; Ken Yamanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-04-03

4.  Bilateral internal mammary arteries: evidence and technical considerations.

Authors:  Michael P Vallely; J James B Edelman; Michael K Wilson
Journal:  Ann Cardiothorac Surg       Date:  2013-07

5.  A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting.

Authors:  Aaron J Weiss; Shan Zhao; David H Tian; David P Taggart; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2013-07

6.  Center-level variation in infection rates after coronary artery bypass grafting.

Authors:  Terry Shih; Min Zhang; Mallika Kommareddi; Theodore J Boeve; Steven D Harrington; Robert J Holmes; Gary Roth; Patricia F Theurer; Richard L Prager; Donald S Likosky
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-07-01

Review 7.  Conduits Used in Coronary Artery Bypass Grafting: A Review of Morphological Studies.

Authors:  Brenda Martínez-González; Cynthia Guadalupe Reyes-Hernández; Alejandro Quiroga-Garza; Víctor E Rodríguez-Rodríguez; Claudia N Esparza-Hernández; Rodrigo E Elizondo-Omaña; Santos Guzmán-López
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-02-14       Impact factor: 1.520

8.  Angiographic appearance of patent saphenous vein grafts more than 25 years after coronary artery bypass grafting.

Authors:  Hiroshi Furukawa; Naoki Yamane; Takeshi Honda; Takahiko Yamasawa; Yuji Kanaoka; Kazuo Tanemoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-11-23

9.  Is there a role for fractional flow reserve in coronary artery bypass graft (CABG) planning?

Authors:  Amir Ahmadi; Dylan Stanger; John Puskas; David Taggart; Y Chandrashekhar; Jagat Narula
Journal:  Ann Cardiothorac Surg       Date:  2018-07

10.  The future of off-pump coronary artery bypass grafting: a North American perspective.

Authors:  Bobby Yanagawa; Rashmi Nedadur; John D Puskas
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.